



PRESS RELEASE

October 20, 2017
Fuji Pharma Co., Ltd.

Approval of partial change application for IOPARQUE® Injections

Fuji Pharma Co., Ltd. announced today that its IOPARQUE® injection, a non-ionic contrast media, obtained Approval for partial change application on October 18.

This Approval makes it possible to start sales in Japan of IOPARQUE® injection in vials that is manufactured by OLIC (Thailand) Limited, a subsidiary of Fuji Pharma.

OLIC (Thailand) is the largest contract manufacturing organization (CMO) in Thailand. The company conducts contract manufacturing for global companies. In January 2017, the company completed construction of a new plant for injectable products. On this occasion, Fuji added the plant as a manufacturing site for IOPARQUE® injection. The new plant is equipped with advanced manufacturing equipment from Japan and Europe. The high quality injection drugs are produced by making use of manufacturing technologies and other expertise that Fuji Pharma has accumulated over many years. This new plant is in compliance with the GMP (Good Manufacturing Practices) of Japan, the PIC/S (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) GMP, cGMP and EU GMP.

The Approval to sell in Japan IOPARQUE® injection manufactured by OLIC (Thailand) will improve Fuji Pharma's ability to supply its key products with consistency. Fuji Pharma also believes this Approval will contribute to its growth.

In addition, OLIC (Thailand) plans to manufacture pharmaceuticals for sale in Thailand and other Southeast Asian countries in the future.

Product name	IOPARQUE® injection
Approval for partial change application	Addition of OLIC (Thailand) as a manufacturing site
Products covered by the partial change	<ul style="list-style-type: none">• IOPARQUE 300® injection 50mL• IOPARQUE 300® injection 100mL• IOPARQUE 350® injection 50mL• IOPARQUE 350® injection 100mL